Q32 Bio Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $270.8M
- Price
- $15.97
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.69%
- Volume
- 341.5K
About
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
Quick stats
Shares outstanding17.0M
Computed float5.6M
Float / shares32.8%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001661998
Websitehttps://www.q32bio.com
AI Summary
AI-generated1/23
majorbullishearnings
Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Q32 Bio reported positive 36-week topline results from Part B of its SIGNAL-AA Phase 2a trial, with bempikibart demonstrating a 35.3% mean reduction in SALT score and 40% of patients achieving SALT-20 response.
The company completed a $200 million public offering in July 2026, bringing total cash to $106.3 million as of June 30, 2026, sufficient to fund operations through Phase 3 topline results.
Q2 net loss improved to $8.9 million from $9.5 million year-over-year, driven by lower R&D expenses following the sale of the ADX-097 program in November 2025.
A registration-directed program in severe or very severe alopecia areata is expected to initiate in the first half of 2027, subject to regulatory discussions in the second half of 2026.